Close

Raymond James on Neurocrine Bio. (NBIX): 'Solid Beat for Ingrezza; Well Positioned Moving Forward'

May 4, 2022 10:24 AM EDT Send to a Friend
Raymond James analyst Danielle Brill reiterated an Outperform rating on Neurocrine Bio. (NASDAQ: NBIX).The analyst comments "Ingrezza 1Q revenues solidly ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login